MDCXW
Medicus Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$0.31
−6.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 20.6M | 7.7M | 3.5M | 193.6K | 646.4K |
| SG&A Expense | 22.7M | 17.9M | 7.7M | 2.5M | 332.0K |
| General & Admin Expense | 22.7M | 17.9M | 7.7M | 2.5M | 332.0K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (5.5M) | (7.3M) | — | 2.1M | — |
| Total Operating Expenses | 37.8M | 18.4M | 11.2M | 4.7M | 978.4K |
| Cost and Expenses | 37.8M | 18.4M | 11.2M | 4.7M | 978.4K |
| Operating Income (EBIT) | (37.8M) | (18.4M) | (11.2M) | (4.7M) | (978.4K) |
| Non-Operating | |||||
| Interest Income | 11.6K | — | 104.4K | 10.7K | (575.4K) |
| Interest Expense | (30.5K) | 141.3K | 317.5K | 595.5K | 526.8K |
| Net Interest Income | 42.1K | (141.3K) | (213.1K) | (584.8K) | (1.1M) |
| Other Non-Op Income/Expense | (1.4M) | (7.0M) | 25.4K | (584.8K) | (714.0K) |
| Non-Operating Income (excl Interest) | 1.5M | 6.9M | (25.4K) | (2.1M) | 187.1K |
| EBT (Pre-Tax Income) | (39.2M) | (25.4M) | (11.2M) | (5.3M) | (1.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (39.1M) | (25.4M) | (11.2M) | (5.3M) | (1.7M) |
| Earnings from Cont. Ops | (39.2M) | (25.4M) | (11.2M) | (5.3M) | (1.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (51.0M) | (33.8M) | (11.2M) | (5.3M) | (1.7M) |
| Per Share | |||||
| Basic EPS | ($1.62) | ($1.96) | ($0.69) | ($0.49) | ($0.16) |
| Diluted EPS | ($1.62) | ($1.96) | ($0.69) | ($0.49) | ($0.16) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 55.1M | 17.3M | 11.8M | 8.1M | 8.1M |
| Diluted Shares Outstanding | 55.1M | 17.3M | 11.8M | 8.1M | 8.1M |
| Profitability Metrics | |||||
| EBITDA | (39.2M) | (25.2M) | (11.2M) | (586.8K) | (1.2M) |
| D&A | — | — | — | 2.1M | — |
| EBIT | (39.2M) | (25.2M) | (11.2M) | (2.7M) | (1.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026